The Armenian Reporter6h
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Sonora Investment Management Group LLC
Sonora Investment Management Group LLC cut its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 21.6% during the 4th quarter, according to its most recent Form 13F filing with the ...
Why Bristol-Myers Squibb Company (BMY) Is Among the Best Long Term Low Risk Stocks to Buy Now
We recently compiled a list of the 12 Best Long Term Low Risk Stocks to Buy Right Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against ...
Jim Cramer's week ahead: Earnings from Amazon, Alphabet, Eli Lilly, Palantir
CNBC's Jim Cramer on Friday walked investors through an earnings-heavy week, highlighting reports from Amazon, Alphabet, Eli ...
Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses
Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...
Le Lézard1d
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...
Bristol Myers gets positive CHMP opinion for Opdivo plus Yervoy
Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...
Le Lézard1d
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
Axsome Therapeutics, Inc. , a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference call today at ...
Bristol Myers’ Breyanzi receives positive CHMP opinion in follicular lymphoma
Bristol Myers (BMY) announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has ...
Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain
Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...
PharmiWeb1d
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with ...
Barchart on MSN1d
What Are Wall Street Analysts' Target Price for Bristol-Myers Squibb Stock?
Bristol-Myers Squibb Company (BMY) is one of the leading biopharmaceutical companies focused on developing treatments for ...
Bristol-Myers Squibb (NYSE:BMY) Price Target Raised to $65.00
Bristol-Myers Squibb (NYSE:BMY – Free Report) had its target price boosted by Citigroup from $60.00 to $65.00 in a report published on Tuesday,Benzinga reports. They currently have a neutral rating on ...